Unjoni Ewropea - Olandiż - EMA (European Medicines Agency)

eli lilly nederland b.v. - baricitinib - artritis, reumatoïde - immunosuppressiva - rheumatoid arthritisbaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). olumiant kan als monotherapie of in combinatie met methotrexaat worden gebruikt. atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy. alopecia areatabaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5. juvenile idiopathic arthritisbaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic dmards:- polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [rf+] or negative [rf-], extended oligoarticular),- enthesitis related arthritis, and- juvenile psoriatic arthritis. baricitinib may be used as monotherapy or in combination with methotrexate.

Unjoni Ewropea - Olandiż - EMA (European Medicines Agency)

angelini pharma s.p.a - cenobamate - epilepsie - van anti-epileptica, - adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic medicinal products.

Unjoni Ewropea - Olandiż - EMA (European Medicines Agency)

pfizer europe ma eeig  - abrocitinib - dermatitis, atopic - andere dermatologische preparaten - cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.

Unjoni Ewropea - Olandiż - EMA (European Medicines Agency)

takeda pharma a/s - brigatinib - carcinoom, niet-kleincellige long - antineoplastische middelen - alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase alkpositive advanced nsclc previously treated with crizotinib.

Unjoni Ewropea - Olandiż - EMA (European Medicines Agency)

novartis europharm limited - ceritinib - carcinoom, niet-kleincellige long - antineoplastische middelen - zykadia is geïndiceerd voor de behandeling van volwassen patiënten met anaplastisch lymfoomkinase (alk) -positieve, geavanceerde niet-kleincellige longkanker (nsclc) die eerder met crizotinib werden behandeld..

Unjoni Ewropea - Olandiż - EMA (European Medicines Agency)

pfizer europe ma eeig - crizotinib - carcinoom, niet-kleincellige long - antineoplastische middelen - xalkori as monotherapy is indicated for:the first‑line treatment of adults with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with previously treated anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with ros1‑positive advanced non‑small cell lung cancer (nsclc)the treatment of paediatric patients (age ≥6 to.

Unjoni Ewropea - Olandiż - EMA (European Medicines Agency)

pfizer europe ma eeig - lorlatinib - carcinoom, niet-kleincellige long - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.

Unjoni Ewropea - Olandiż - EMA (European Medicines Agency)

roche registration gmbh - alectinib hydrochloride - carcinoom, niet-kleincellige long - antineoplastische middelen - alecensa als monotherapie is geïndiceerd voor eerstelijns behandeling van volwassen patiënten met een anaplastisch lymfoom kinase (alk)-positieve gevorderde niet-kleincellige longkanker (niet-kleincellig longcarcinoom). alecensa als monotherapie is geïndiceerd voor de behandeling van volwassen patiënten met alk‑positieve gevorderde niet-kleincellig longcarcinoom eerder behandeld met crizotinib.

Olanda - Olandiż - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

pharmachemie b.v. swensweg 5 2031 ga haarlem - tacrolimus 1-water 0,51 mg/stuk samenstelling overeenkomend met ; tacrolimus 0-water 0,5 mg/stuk - capsule, hard - croscarmellose natrium (e 468) ; gelatine (e 441) ; ijzeroxide geel (e 172) ; lactose 0-water ; magnesiumstearaat (e 470b) ; povidon k 30 (e 1201) ; titaandioxide (e 171), - tacrolimus

Olanda - Olandiż - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

pharmachemie b.v. swensweg 5 2031 ga haarlem - tacrolimus 1-water 1,02 mg/stuk samenstelling overeenkomend met ; tacrolimus 0-water 1 mg/stuk - capsule, hard - croscarmellose natrium (e 468) ; gelatine (e 441) ; lactose 0-water ; magnesiumstearaat (e 470b) ; povidon k 30 (e 1201) ; titaandioxide (e 171), - tacrolimus